◎ Sugi Atlas

Atlas / Drug / Meloxicam

Meloxicam

drug
On this page

Also known as ActicamAnjesoContaceraCoxicamEmdocamFlexicamInflacamLoxicomLoxitabMelfaxMelosusMelovemMeloxicam component of zelerisMeloxicam component of zynrelefMeloxidolorMeloxidylMeloxivetMeloxoralMetacam

Summary

Meloxicam (CHEMBL599) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AC56) targeting PTGS1 and PTGS2; indicated across 17 conditions including rheumatic disorder and rheumatoid arthritis; with CIViC clinical evidence for 2 variant-indication associations (e.g. CTNNB1 T41A in desmoid tumor).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: M01AC56 (+1 more)
  • Targets: 2 (PTGS1, PTGS2)
  • Indications: 17 conditions
  • Clinical trials: 79
  • Precision-oncology evidence (CIViC): 2 variant–indication associations
  • Chemistry: 351.4 Da · C14H13N3O4S2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL599
NameMeloxicam
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID54677470
ChEBICHEBI:6741
ATCM01AC56, M01AC06
Molecular formulaC14H13N3O4S2
Molecular weight351.4
InChIKeyZRVUJXDFFKFLMG-UHFFFAOYSA-N

SMILES: CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O

IUPAC name: 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide

ChEBI definition: A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, antirheumatic drug, cyclooxygenase 2 inhibitor, analgesic.

Also known as: Acticam, Anjeso, Contacera, Coxicam, Emdocam, Flexicam, Inflacam, Loxicom, Loxitab, Melfax, Melosus, Melovem

Parent form; salt/anhydrous children: CHEMBL1256873, CHEMBL1898907

Patent coverage: 12,835 distinct patent families (50,000 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 49,652 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS1COX-1Inhibition4.440%P23219
PTGS2COX-2Inhibition6.310%P35354

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Beta-lactamase, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Endothelin-1 receptor, Alpha-galactosidase A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 2, Bile salt export pump.

Bioactivity

ChEMBL activities: 18 potent at pChembl ≥ 5 of 31 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PTGS17.45IC5035.41nMCHEMBL_ACT_29310239
PTGS27.28IC5052.35nMCHEMBL_ACT_29310234
Q057696.82IC50151.4nMCHEMBL_ACT_16804599
PTGS26.8IC50160nMCHEMBL_ACT_246443
PTGS26.48IC50330nMCHEMBL_ACT_22875960
PTGS26.31IC50490nMCHEMBL_ACT_1248505
PTGS26.31IC50490nMCHEMBL_ACT_25650366
PTGS26.31IC50490nMCHEMBL_ACT_25708403
PTGS26.16IC50700nMCHEMBL_ACT_1080912
PTGS26.03IC50938nMCHEMBL_ACT_7760084
P059796IC501000nMCHEMBL_ACT_16804598
PTGS15.88IC501319nMCHEMBL_ACT_7760082
P792085.86IC501370nMCHEMBL_ACT_16382547
PTGS15.85IC501400nMCHEMBL_ACT_1080913
PTGS15.66IC502200nMCHEMBL_ACT_246444
PTGS25.62IC502400nMCHEMBL_ACT_25035251
PTGS25.25AC505684nMCHEMBL_ACT_25166175
PTGS25.12IC507580nMCHEMBL_ACT_25594147

Target pathways

Aggregated over 2 target gene(s): PTGS1, PTGS2.

Top Reactome pathways

9 total, by targets touching each:

PathwayTargetsGenes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)2PTGS1, PTGS2
COX reactions1PTGS1
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2

Dominant GO biological processes

GO termTargets
prostaglandin biosynthetic process2
response to oxidative stress2
regulation of blood pressure2
cyclooxygenase pathway2
regulation of cell population proliferation2
long-chain fatty acid biosynthetic process2
lipid metabolic process2
fatty acid metabolic process2
fatty acid biosynthetic process2
prostaglandin metabolic process2
prostanoid biosynthetic process2
cellular oxidant detoxification2
embryo implantation1
response to nematode1
response to selenium ion1

Indications & clinical

Indications

17 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
rheumatic disorder4MONDO:0005554EFO:0005755
rheumatoid arthritis4MONDO:0008383EFO:0000685
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
osteoarthritis4MONDO:0005178MONDO:0005178
ankylosing spondylitis3MONDO:0005306EFO:0003898
prostate adenocarcinoma3MONDO:0005082EFO:0000673
migraine disorder3MONDO:0005277MONDO:0005277
tuberculosis3MONDO:0018076MONDO:0018076
pharyngitis2MONDO:0002258MONDO:0002258
osteoarthritis, knee2MONDO:0005416EFO:0004616
systemic lupus erythematosus1MONDO:0007915MONDO:0007915

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 79.

Phase distribution

PhaseTrials
PHASE324
PHASE115
PHASE213
Not specified13
PHASE412
PHASE2/PHASE32

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06704113PHASE4NOT_YET_RECRUITINGMeloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients
NCT07158476PHASE4RECRUITINGEfficacy of Methylprednisolone for Pain Control After ACL Repair
NCT07200544PHASE4RECRUITINGMeloxicam in Mohs Micrographic Surgery
NCT00635349PHASE4COMPLETEDA Comparative Study of Tramadol Hydrochloride Plus Acetaminophen Tablets Maintenance Versus Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Maintenance in Participants With Knee Osteoarthritis
NCT02183116PHASE4COMPLETEDA Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee
NCT02183129PHASE4COMPLETEDStudy to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee
NCT02229747PHASE4COMPLETEDEfficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis
NCT02298218PHASE4COMPLETEDClinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia
NCT03473665PHASE4TERMINATEDNon-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis
NCT04766996PHASE4TERMINATEDPROUD Study - Preventing Opioid Use Disorders
NCT05315479PHASE4TERMINATEDSafety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery
NCT05974501PHASE4COMPLETEDPre vs Post Block in Total Knee Arthroplasty (TKA)
NCT00034853PHASE3COMPLETEDMeloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
NCT00042068PHASE3COMPLETEDA Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
NCT00152919PHASE3COMPLETEDMobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy
NCT00239382PHASE3COMPLETEDA Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis
NCT00239395PHASE3COMPLETEDA Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis
NCT00279747PHASE3COMPLETEDA One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
NCT01147289PHASE3COMPLETEDEfficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain
NCT01436032PHASE3TERMINATEDEfficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery
NCT01587508PHASE3WITHDRAWNStudy Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago
NCT01787188PHASE3COMPLETEDStudy of Meloxicam Capsules to Treat Osteoarthritis Pain
NCT01801735PHASE3COMPLETEDStudy of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip
NCT02183064PHASE3COMPLETEDStudy to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
NCT02183168PHASE3COMPLETEDEvaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
NCT02255045PHASE2/PHASE3COMPLETEDAssessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea
NCT02448199PHASE3UNKNOWNStudy of Association of Anti-inflammatory and Anti-rheumatic
NCT02675907PHASE3COMPLETEDEvaluation of N1539 Following Bunionectomy Surgery
NCT02678286PHASE3COMPLETEDEvaluation of N1539 Following Abdominoplasty Surgery
NCT02706054PHASE3COMPLETEDTreatment of Recent Onset Low Back Pain With Periradicular Injections of Meloxicam
NCT02720692PHASE3COMPLETEDEvaluation of N1539 Following Major Surgery
NCT03323385PHASE3COMPLETEDEvaluation of Preoperative N1539 in Colorectal Surgery
NCT03434275PHASE3COMPLETEDEvaluation of Preoperative N1539 in Total Knee Arthroplasty
NCT03586934PHASE3WITHDRAWNMultimodal Analgesia in Shoulder Arthroplasty
NCT03896009PHASE3COMPLETEDMaximizing Outcomes in Treating Acute Migraine
NCT04480359PHASE2/PHASE3UNKNOWNBawei Shenqi Pill in the Treatment of Ankylosing Spondylitis
NCT04725357PHASE3UNKNOWNDoes Meloxicam Provide as Much Pain Relief as Opioids After Shoulder Surgery?
NCT06904248PHASE3COMPLETEDEfficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery
NCT05695352PHASE2RECRUITINGOral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
NCT06306131PHASE2RECRUITINGPhase II Study of Ovulation in Obese Women

Clinical evidence (CIViC)

Variant × indication × effect (2 predictive associations from 2 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
CTNNB1 T41ADesmoid TumorSensitivity/ResponseMeloxicamCIViC BEID6050
CTNNB1 S45FDesmoid TumorSensitivity/ResponseMeloxicamCIViC CEID6049

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

407 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS1, PTGS2
ASPIRINChEMBLPhase 4 (approved)PTGS1, PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS1, PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
CELECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DICLOFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1, PTGS2
DOXORUBICINChEMBLPhase 4 (approved)PTGS1, PTGS2
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
ETODOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
ETORICOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
GLAFENINEChEMBLPhase 4 (approved)PTGS1, PTGS2
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1, PTGS2
IBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
INDOMETHACINChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOROLACChEMBLPhase 4 (approved)PTGS1, PTGS2
LEVODOPAChEMBLPhase 4 (approved)PTGS1, PTGS2
LOXOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MOFEZOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
MONOBENZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
NAPROXENChEMBLPhase 4 (approved)PTGS1, PTGS2
NIMESULIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
OMADACYCLINEChEMBLPhase 4 (approved)PTGS1, PTGS2
OXAPROZINChEMBLPhase 4 (approved)PTGS1, PTGS2
PIROXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
PRIMAQUINEChEMBLPhase 4 (approved)PTGS1, PTGS2
RANITIDINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ROFECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
SELINEXORChEMBLPhase 4 (approved)PTGS1, PTGS2
SUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
TEGASERODChEMBLPhase 4 (approved)PTGS1, PTGS2
TELOTRISTATChEMBLPhase 4 (approved)PTGS1, PTGS2
TOLMETINChEMBLPhase 4 (approved)PTGS1, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
VALDECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
VORTIOXETINEChEMBLPhase 4 (approved)PTGS1, PTGS2
CURCUMINChEMBLPhase 3PTGS1, PTGS2
RESVERATROLChEMBLPhase 3PTGS1, PTGS2
CIMICOXIBChEMBLPhase 2PTGS1, PTGS2
DERACOXIBChEMBLPhase 2PTGS1, PTGS2
ENOFELASTChEMBLPhase 2PTGS1, PTGS2
FIROCOXIBChEMBLPhase 2PTGS1, PTGS2
FLUFENAMIC ACIDChEMBLPhase 2PTGS1, PTGS2
LICOFELONEChEMBLPhase 2PTGS1, PTGS2
MAVACOXIBChEMBLPhase 2PTGS1, PTGS2
MIROPROFENChEMBLPhase 2PTGS1, PTGS2
NIFLUMIC ACIDChEMBLPhase 2PTGS1, PTGS2
PHENOTHIAZINEChEMBLPhase 2PTGS1, PTGS2
PIRMAGRELChEMBLPhase 2PTGS1, PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot